Literature DB >> 11833081

Expression and bioactivity identification of soluble MG7 scFv.

Zhao-Cai Yu1, Jie Ding, Bo-Rong Pan, Dai-Ming Fan, Xue-Yong Zhang.   

Abstract

AIM: To examine the molecular mass and identify the bioactivity of MG7 scFv for its application as a targeting mediator in gene therapy of gastric cancer.
METHODS: Two strongly positive recombinant phage clones screened from MG7 recombinant phage antibody library were separately transfected into E.coli TG1. Plasmid was isolated from the transfected E.coli TG1 and digested by EcoR I and Hind III to examine the length of exogenous scFv gene. Then, the positive recombinant phage clones were individually transfected into E.coli HB2151. The transfectant was cultured and induced by IPTG. Perplasmic extracts was prepared from the induced transfectant by osmotic shock. ELISA was used to examine the antigen-binding affinity of the soluble MG7 scFv. Immunodotting assay was adopted to evaluate the yield of soluble MG7 scFv produced by transfected E.coli HB2151. Western blot was used to examine the molecular mass of MG7 scFv. Finally, the nucleotide sequence of MG7 scFv was examined by DNA sequencing.
RESULTS: Two positive recombinant phage clones were found to contain the exogenous scFv gene. ELISA showed that MG7 scFv had strong antigen-binding affinity. Immuodotting assay showed that transfected E.coli HB2151 could successfully produce the soluble MG7 scFv with high yield via induction by IPTG. The molecular mass of MG7 scFv was 30 kDa by western blot. DNA sequencing demonstrated that the VH and VL genes of MG7 scFv were 363 bp and 321 bp,respectively.
CONCLUSION: We have successfully developed the soluble MG7 scFv which possessed strong antigen-binding affinity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11833081      PMCID: PMC4656636          DOI: 10.3748/wjg.v8.i1.99

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  45 in total

1.  Differential expression of a novel colorectal cancer differentiation-related gene in colorectal cancer.

Authors:  X G Li; J D Song; Y Q Wang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  Overexpression of P-glycoprotein in hepatocellular carcinoma and its clinical implication.

Authors:  Xian-Bing Kong; Zu-Kui Yang; Li-Jian Liang; Jie-Fu Huang; Han-Liang Lin
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

3.  The Hsp90 chaperone complex A potential target for cancer therapy?

Authors:  Beatrice D Darimont
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

4.  The prognostic value of preoperative serum levels of CEA, CA19-9 and CA72-4 in patients with colorectal cancer.

Authors:  C X Zheng; W H Zhan; J Z Zhao; D Zheng; D P Wang; Y L He; Z Q Zheng
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

5.  Antihepatoma effect of alpha-fetoprotein antisense phosphorothioate oligodeoxyribonucleotides in vitro and in mice.

Authors:  X W Wang; J H Yuan; R G Zhang; L X Guo; Y Xie; H Xie
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

6.  Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy.

Authors:  Y C Tang; Y Li; G X Qian
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

Review 7.  Generating improved single-chain Fv molecules for tumor targeting.

Authors:  G P Adams; R Schier
Journal:  J Immunol Methods       Date:  1999-12-10       Impact factor: 2.303

8.  Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx.

Authors:  S Mao; C Gao; C H Lo; P Wirsching; C H Wong; K D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

9.  Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice.

Authors:  H Romanczuk; C E Galer; J Zabner; G Barsomian; S C Wadsworth; C R O'Riordan
Journal:  Hum Gene Ther       Date:  1999-11-01       Impact factor: 5.695

10.  Human recombinant single-chain antibody fragments, specific for the hypervariable region 1 of hepatitis C virus, from immune phage-display libraries.

Authors:  W Zhai; J Davies; D Z Shang; S W Chan; J P Allain
Journal:  J Viral Hepat       Date:  1999-03       Impact factor: 3.728

View more
  3 in total

1.  Construction and characterization of a novel fusion protein MG7-scFv/SEB against gastric cancer.

Authors:  Qiang Tong; Ke Liu; Xiao-Ming Lu; Xiao-Gang Shu; Guo-Bin Wang
Journal:  J Biomed Biotechnol       Date:  2010-03-22

Review 2.  Gene therapy for gastric cancer: a review.

Authors:  Chao Zhang; Zhan-Kui Liu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

3.  Construction and identification of recombinant vectors carrying herpes simplex virus thymidine kinase and cytokine genes expressed in gastric carcinoma cell line SGC7901.

Authors:  Jian-Hua Zhang; Ming-Xi Wan; Jia-Ying Yuan; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.